Dr. Dorritie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5115 Centre Avenue
5th Floor, Upmc Cancer Pavillion
Pittsburgh, PA 15232Phone+1 412-692-4724- Is this information wrong?
Summary
- Dr. Kathleen Dorritie is an oncologist in Pittsburgh, PA and is affiliated with multiple hospitals in the area, including Shadyside Campus, UPMC Magee-Womens Hospital, and UPMC Presbyterian. She received her medical degree from SUNY Upstate Medical University and has been in practice 10 years. She specializes in hematologic oncology and is experienced in hematologic malignancies and cellular immunotherapy.
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2010 - 2013- UPMC Medical EducationResidency, Internal Medicine, 2007 - 2010
SUNY Upstate Medical UniversityClass of 2007
Certifications & Licensure
PA State Medical License 2007 - 2024- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Stem Cell Transplant in Patients With Severe Sickle Cell Disease Start of enrollment: 2018 Mar 29
Publications & Presentations
PubMed
- Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.Normolle, D., Bovbjerg, D., Im, A., Quann, K., Agha, M., Raptis, A., Redner, R., Hou, J., Farah, R., Dorritie, K., Sehgal, A., Aggarwal, N., Herman, J., Lontos, K., Bo...> ;American Journal of Hematology. 2024 Mar 1
- Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.Sanjal H Desai, Michael A Spinner, Andrew M Evens, Alice Sykorova, Veronika Bachanova, Gaurav Goyal, Brad Kahl, Kathleen Dorritie, Jacues Azzi, Vaishalee P Kenkre, Che...> ;Blood Advances. 2023 Dec 12
- 3 citationsMosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.Budde, L., Olszewski, A., Assouline, S., Lossos, I., Diefenbach, C., Kamdar, M., Ghosh, N., Modi, D., Sabry, W., Naik, S., Mehta, A., Nakhoda, S., Smith, S., Dorritie,...> ;Nature Medicine. 2024 Jan 1
- Join now to see all
Press Mentions
BELINDA Trial Tests Earlier Use of Tisa-Cel in Aggressive B-cell Non-Hodgkin LymphomaDecember 20th, 2019- The Untold Story of the Longest Persisting CAR-T Cells in CLLMay 20th, 2019
The AMA Does Not Speak for UsDecember 9th, 2016
Hospital Affiliations
- Shadyside CampusPittsburgh, Pennsylvania
UPMC Magee-Womens HospitalPittsburgh, Pennsylvania
UPMC Presbyterian ShadysidePittsburgh, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
